P. Rogers

The safety profile of anti‐tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient‐years follow‐up

Charlie W. Lees, Amouri Ali, Alexandra Thompson et al. · Alimentary Pharmacology & Therapeutics · 2008 · 123 citations

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol

Gerhardt Attard, Laura Murphy, Noel W. Clarke et al. · The Lancet Oncology · 2023 · 85 citations · Full text

Clinical and cellular ionizing radiation sensitivity in a patient with xeroderma pigmentosum

C.F. Arlett, P.N. Plowman, P. Rogers et al. · British Journal of Radiology · 2006 · 46 citations

Radiation Effect, Radiation Exposure, Pathology +21

Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

Chris Parker, Noel W. Clarke, Adrian Cook et al. · The Lancet · 2024 · 43 citations · Full text

Variations in neurodegenerative disease across the UK: findings from the national study of Progressive Intellectual and Neurological Deterioration (PIND).

G. Devereux, L Stellitano, Christopher Verity et al. · PubMed · 2004 · 40 citations